Health & Fitness
Health and Fitness
Health and Fitness
Fri, October 15, 2010
Thu, October 14, 2010
BioSante Pharmaceuticals, Inc. To Present at Cancer Immunotherapy Conference
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.
"Cancer Vaccine Therapies: Failures and Future Opportunities"
Stephen M. Simes, BioSantea™s president & chief executive officer, will speak at 11:00 am EDT, and will provide an overview of BioSantea™s portfolio of cancer vaccines currently in multiple Phase II clinical trials, as well as comment on the receipt of FDA orphan drug designation received for several of the cancer vaccines.
The agenda for the Cancer Immunotherapy:A Long Awaited Reality conference includes keynotes and plenary discussions, roundtable lunch conversations with experts, a focused science and industry track, as well as networking opportunities. The conference will be hosted by MD Becker Partners and BioBusiness.TV. There will be a corresponding live webcast of the conference, which can be accessed by visiting [ http://www.mdbpartners.com/vaccine ]. Jill Oa™Donnell-Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), is scheduled to present a keynote address titled aThe Future of Cancer Vaccine Development.a
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrina" (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSantea™s licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLooka"), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: [ www.biosantepharma.com ].
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. In early April 2010, MD Becker Partners published a 150-page industry report titled aCancer Vaccine Therapies: Failures and Future Opportunities,a which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discussion of the scientific, clinical, and commercial considerations for major industry participants. For more information visit [ http://www.mdbpartners.com ].
About BioBusiness.TV
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. For more information, visit [ http://www.biobusiness.tv ].
